IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Webhead who wrote (496)	3/20/1997 12:37:00 PM
From: Pseudo Biologist	of 1762

Ed you commented (on the IDEC-PDL announcement): "I don't know what impact this will have on IDEC since we don't even know which antibody this is for! I hope that this doesn't mean that IDEC's primatized antibodies will each require licenses" As "the cat in the hat" would say "have no fear;" I think your hope should be fulfilled. If you read IDEC's most recent prospectus for their follow-on offering (of at least 6 months ago), they do mention the possibility of having to take out a license for their humanized Abs (these are genetically engineered, usually from mouse or rat, and involve modification of the variable domains of the Abs -- the "tips" in the usual Y diagram). I understand that most of IDEC's Abs are "primatized" in which the engineering does not change the variable domains (which are derived from non-human primate); in other words the "tips" are taken entirely from the animal's Ab without further engineering: this is the key difference with humanized molecules. If you take the tips from lower animals such as mice one probably does need to keep working on these "tips" If you take them from a monkey, you are already close enough to a human-like molecule such that further work on the "tips" is probably not required -- to reduce immunogenecity. These primatized molecules are not covered by PDL's patents; in fact, I think IDEC has, at least, patent applications of their own covering the "primatization" procedure. On a more positive note, the fact that IDEC is willing to cough up a million bucks right now (PDL charges you more as your molecule gets closer to marketing approval) suggests very strongly that they have good hopes for this molecule (which is neither the anti-lymphoma nor the primatized Ab whose good phase II results in RA were announced some time ago). I think an examination of the prospectus mentioned above (available at the SEC site) could give you a pretty good idea of what this molecule (subject of the PDL license) may be. More general information on antibodies may be found at www-chem.ucsd.edu this site has links to places explaining chimeric, humanized Abs, etc. Max

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next